{"id":633767,"date":"2023-01-12T19:02:01","date_gmt":"2023-01-12T19:02:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=633767"},"modified":"2023-01-12T19:02:01","modified_gmt":"2023-01-12T19:02:01","slug":"regenerative-medicine-market-worth-406-billion-by-2027-exclusive-report-by-marketsandmarkets","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/regenerative-medicine-market-worth-406-billion-by-2027-exclusive-report-by-marketsandmarkets_633767.html","title":{"rendered":"Regenerative Medicine Market worth $40.6 billion by 2027 – Exclusive Report by MarketsandMarkets\u2122"},"content":{"rendered":"
\n
\"Regenerative<\/a><\/div>\n
\n
The regenerative medicine market is consolidated in nature with prominent players in the regenerative medicine market include Novartis AG (Switzerland), Biogen (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen, Inc. (US), Smith & Nephew plc (UK), Medipost Co., Ltd. (South Korea)<\/div>\n<\/div>\n<\/div>\n
In 2022, Novartis announces collaboration with Alnylam to explore targeted therapy to restore liver function.<\/div>\n

Regenerative Medicine Market<\/a><\/strong> is projected to reach USD 40.6 billion by 2027 from USD 12.2 billion in 2022, at a CAGR of 27.2% according to a new report by MarketsandMarkets™. <\/strong>The major factors driving the growth of the regenerative medicine market are the availability of funding and rising investments in R&D, increasing clinical trials for stem cells and CAR-T cell therapies, and rising advancements in tissue engineered products.<\/p>\n

Download PDF Brochure: https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=65442579<\/a><\/strong><\/p>\n

Browse in-depth TOC on “Regenerative Medicine Market”<\/strong><\/p>\n

193 – Tables<\/strong><\/p>\n

49 – Figures<\/strong><\/p>\n

192 – Pages<\/strong><\/p>\n

Regenerative Medicine Market Scope:<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Report Coverage<\/strong><\/p>\n<\/td>\n

\n

Details<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Market Size<\/p>\n<\/td>\n

\n

USD 40.6 billion by 2027<\/p>\n<\/td>\n<\/tr>\n

\n

Growth Rate<\/p>\n<\/td>\n

\n

27.2% of CAGR<\/p>\n<\/td>\n<\/tr>\n

\n

Largest Market<\/p>\n<\/td>\n

\n

North America<\/p>\n<\/td>\n<\/tr>\n

\n

Market Dynamics<\/p>\n<\/td>\n

\n

Drivers, Restraints, Opportunities & Challenges<\/p>\n<\/td>\n<\/tr>\n

\n

Forecast Period<\/p>\n<\/td>\n

\n

2022-2027<\/p>\n<\/td>\n<\/tr>\n

\n

Forecast Units<\/p>\n<\/td>\n

\n

Value (USD Billion)<\/p>\n<\/td>\n<\/tr>\n

\n

Report Coverage<\/p>\n<\/td>\n

\n

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends<\/p>\n<\/td>\n<\/tr>\n

\n

Segments Covered<\/p>\n<\/td>\n

\n

Product, Application, and Region <\/p>\n<\/td>\n<\/tr>\n

\n

Geographies Covered<\/p>\n<\/td>\n

\n

North America, Europe, Asia Pacific, Latin America, Middle East & Africa<\/p>\n<\/td>\n<\/tr>\n

\n

Report Highlights<\/p>\n<\/td>\n

\n

Updated financial information \/ product portfolio of players<\/p>\n<\/td>\n<\/tr>\n

\n

Key Market Opportunities<\/p>\n<\/td>\n

\n

Implementation of the 21st Century Cures Act<\/p>\n<\/td>\n<\/tr>\n

\n

Key Market Drivers<\/p>\n<\/td>\n

\n

Growing prevalence of chronic diseases, genetic disorders, and cancer<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Request Sample Pages: https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=65442579<\/a><\/strong><\/p>\n

Cell therapy segment accounted for the largest share of the regenerative medicine market<\/strong><\/p>\n

Based on the product, the regenerative medicine market is segmented into musculoskeletal disorders, oncology, dermatology & wound care, ophthalmology, cardiovascular diseases, and other applications. In 2021, the musculoskeletal disorders segment accounted for the largest share of the global regenerative medicine market. Growth in this market segment can be attributed to the rising research on musculoskeletal regeneration and prevalence of orthopedic disorders.<\/p>\n

Musculoskeletal disorder is the largest-growing application segment of the regenerative medicine market<\/strong><\/p>\n

Based on application, the regenerative medicine market is segmented into academic & research institutes, contract research organizations (CROs), and pharmaceutical & biotechnology companies. In 2021, the academic & research institutes segment accounted for the largest share of the regenerative medicine market. Market growth can largely be attributed to the increase in research intensity in this end-user segment and the availability of sufficient grants and funds for research.<\/p>\n

North America accounted for the largest share of the regenerative medicine market<\/strong><\/p>\n

North America held the largest share in the global market, followed by Europe. The large share of the North American regional segment can be attributed to the increase in research targeted toward developing cell-based therapies in the past decade and increasing research activities in regenerative medicine and growing awareness of personalized medicine have also resulted in the establishment of stem cell banking and tissue engineering.<\/p>\n

Regenerative Medicine Market Dynamics:<\/strong><\/p>\n

Drivers:<\/strong><\/p>\n

    \n
  1. Rising prevalence of chronic diseases, genetic disorders, and cancer<\/li>\n
  2. Rising investments in regenerative medicine research<\/li>\n
  3. Growing pipeline of regenerative medicine products<\/li>\n<\/ol>\n

    Restraints:<\/strong><\/p>\n

      \n
    1. Ethical concerns related to the use of embryonic stem cells in research & development<\/li>\n
    2. High cost of cell and gene therapies<\/li>\n<\/ol>\n

      Opportunities:<\/strong><\/p>\n

        \n
      1. Implementation of the 21st Century Cures Act<\/li>\n
      2. Rising demand for organ transplantations<\/li>\n<\/ol>\n

        Key Market Players:<\/strong><\/p>\n

        The regenerative medicine market is consolidated in nature with prominent players in the regenerative medicine market include Novartis AG (Switzerland), Biogen (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen, Inc. (US), Smith & Nephew plc (UK), Medipost Co., Ltd. (South Korea), JCR Pharmaceuticals Co., Ltd (Japan), Takeda Pharmaceutical Company (Japan), CORESTEM, Inc (South Korea), Vericel Corporation (US), MIMEDX (US), Organogenesis Inc. (US), Medtronic plc (US), Orthocell Ltd. (Australia), Mesoblast Ltd (Australia), BioRestorative Therapies, Inc (US), Pluri Inc. (Israel),  Tegoscience  (South Korea), Anterogen Co., Ltd. (South Korea), bluebird bio, Inc. (US), APAC Biotech (India), Shenzhen SiBiono Genetech Co., Ltd. (China), Aspect Biosystems (Canada), and Athersys, Inc. (US).<\/p>\n

        Recent Developments:<\/strong><\/p>\n